Trial
NCT01010568
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Georgetown University
Collaborators
GlaxoSmithKline; Cephalon
Condition
Chronic Lymphocytic Leukemia
Intervention
Ofatumumab and Bendamustine
Why stopped
Unable to accrue patients due to change in standard CLL therapy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-12-15